Saturday, 31 October 2026European Markets

EIFFAGE And PRECIA Have A High Dividend Yield And Return On Equity In The Industrials Sector.

Loading stream...

(vianews) - eiffage (fgr.pa) is among this list of stock assets with the highest dividend rate and return on equity on the industrials sector.

financial asset price forward dividend yield return on equity
eiffage (fgr.pa) €99.40 3.39% 19.06%
precia (prec.pa) €29.20 1.48% 7.49%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. eiffage (fgr.pa)

3.39% forward dividend yield and 19.06% return on equity

eiffage sa engages in the construction, property development, urban development, civil engineering, metallic construction, roads, energy systems, and concessions businesses in france and internationally. the company construction segment offers urban development, building design and construction, property development, and maintenance and services works. its infrastructure segment is involved in undertaking civil engineering, road and rail design and construction, drainage, earthworks, and metallic construction. the company's energy systems segment designs, constructs, integrates, operates, and maintains energy and telecommunication systems and equipment. its concessions segment constructs and manages concession contracts and public-private partnerships. the company was incorporated in 1920 and is headquartered in vélizy-villacoublay, france.

earnings per share

as for profitability, eiffage has a trailing twelve months eps of €9.36.

pe ratio

eiffage has a trailing twelve months price to earnings ratio of 10.62. meaning, the purchaser of the share is investing €10.62 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.06%.

revenue growth

year-on-year quarterly revenue growth grew by 7.9%, now sitting on 20.87b for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, eiffage's stock is considered to be overbought (>=80).

dividend yield

as claimed by morningstar, inc., the next dividend payment is on may 15, 2023, the estimated forward annual dividend rate is 3.6 and the estimated forward annual dividend yield is 3.39%.

more news about eiffage.

2. precia (prec.pa)

1.48% forward dividend yield and 7.49% return on equity

precia s.a. designs, manufactures, sells, and services weighing solutions. the company offers industrial weighing scales, such as ready to weigh, postal scales, laboratory scales, load receptor, and access range products; user interfaces and displays, including slave and remote displays, and weighing indicators; vehicle weighing and access control products, including weighbridges, weighbridges indicators and displays, driver terminals, and accessories, as well as truckflow, a weighbridge and in/out weighing management software; on board weighing systems for industrial vehicles; and dynamic weight control solutions. it also provides tank weighing products, such as process weighing load cells and indicators; weighing stations for the manual and automatic dosing of ingredients associated with manufacturing formulas; average weight control products; bulk continuous weighing products comprising belt scales, weighing conveyors, belt speed conveyor measurement devices, weighing controllers, multi-station and modular belt weighers, single-station structure scales, and belt scale with conveyors, as well as databulk bs, a continuous weighing supervision software; and bulk discontinuous weighing, such as automatic bulk scales, discontinuous weighing controllers, and weighing indicators, as well as databulk abs, an automatic bulk scale software product. in addition, the company offers bulk dosing products, including gravimetric dosing, dosing electronic system, volumetric dosing, and soft blending products; weighing products for hazardous areas; pm connected services; smartphone applications, including weigh2flow for analyzing flow rates of your conveyors, and weigh2control to monitor and centralize weighing information; and dimensioning weighing scanning. it serves agribusiness, food processing, waste management, transport and logistics, and extractive industries worldwide. precia s.a. was founded in 1887 and is headquartered in privas, france.

earnings per share

as for profitability, precia has a trailing twelve months eps of €1.04.

pe ratio

precia has a trailing twelve months price to earnings ratio of 28.08. meaning, the purchaser of the share is investing €28.08 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.49%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 28, 2022, the estimated forward annual dividend rate is 0.4 and the estimated forward annual dividend yield is 1.48%.

more news about precia.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com